Navigation Links
Perrigo Confirms That its Partner Synthon Has Filed for Generic Version of Xyzal(R) Solution and Announcement of Lawsuit by Sepracor/UCB
Date:6/24/2009

ents. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 28, 2008, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Perrigo Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Perrigo Reports Record Third Quarter
2. Perrigo Company Announces Quarterly Dividend
3. Perrigo Announces FDA Approval for Sulfacetamide Sodium Topical Suspension USP, 10% (Lotion)
4. Perrigo Begins Shipments of Ibuprofen PM
5. Perrigo Reports Record Second Quarter Sales
6. Perrigo Company Announces Quarterly Dividend
7. Perrigo Company Appointed Generic Distributor by Medimetriks Pharmaceuticals
8. Perrigo Company Will Release Second Quarter Fiscal Year 2009 Results on February 3, 2009
9. Perrigo Company to Present at the 27th Annual JPMorgan Healthcare Conference
10. Perrigo Announces FDA Final Approval for Ibuprofen PM
11. Perrigo Settles Desloratadine Patent Litigation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... , ... " Core Organizer ” was featured on NewsWatch as part of ... the market for iOS, Android, and Windows. Joe Toohey, the host of AppWatch and ... help anyone get organized. , Wouldn’t it be great if everyone could be a ...
(Date:7/29/2015)... Park, Pa. (PRWEB) , ... July 29, 2015 ... ... education services for autism. Parents, educators and service providers of children living with ... practices to better serve the growing demographic. , The National Autism Conference ...
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... According to ... flies revealed a gene which is directly responsible for stimulating and perpetuating alcohol use ... in the journal entitled Proceedings of the National academy of Sciences, and has given ...
(Date:7/29/2015)... ... July 29, 2015 , ... With a new ... up with Stillwaters Cancer Support Services and announced a new charity campaign to ... family counseling, support groups, workshops and educational programs at no charge. Scott ...
(Date:7/29/2015)... ... July 29, 2015 , ... Wedding season is in full swing, which means bridal ... pressure of looking good on the big day. Every bride wants to look and feel ... level. , According to a recent study by the American Academy ...
Breaking Medicine News(10 mins):Health News:Get More Organized with the Core Organizer App 2Health News:Penn State Conference to Address Instruction, Success for Children with Autism 2Health News:Study Reveals Potential for Gene Manipulation to Stop Alcohol Addiction 2Health News:Study Reveals Potential for Gene Manipulation to Stop Alcohol Addiction 3Health News:Scott Campbell Agency and Nonprofit Stillwaters Cancer Support Services Initiate New Charity Campaign in Waukesha, WI to Provide Help for People Touched by Cancer 2Health News:Scott Campbell Agency and Nonprofit Stillwaters Cancer Support Services Initiate New Charity Campaign in Waukesha, WI to Provide Help for People Touched by Cancer 3Health News:Say I Do To Surgery: Bridal Beauty On The Rise According to New Survey 2Health News:Say I Do To Surgery: Bridal Beauty On The Rise According to New Survey 3
... ANGELES, Oct. 3 Pink tags will be ... the supermarket chain partners,with vendors and suppliers to ... Throughout the month, pink tags can be found ... identify participating products,customers can purchase to support breast ...
... Interested in Stopping their Periods, But Unsure,About Medical Implications, ... of,women in a national survey say that they are ... aren,t sure if it,s safe. Yet when,physicians are polled, ... menstruation is, in fact, medically safe and,acceptable. The survey ...
... than the two thirds of the women in a ... their menstrual periods but many of them arent sure ... percent say that continuous oral contraceptive therapy to suppress ... survey results were presented by Kurt Barnhart MD, MSCE ...
... QUINCY, Mass., Oct. 3 The Stop & Shop Supermarket,Company, ... $75,000 to,Susan G. Komen for the Cure with the Pink ... Month," said Stop & Shop/Giant,Consumer Advisor Andrea Astrachan, "and by ... Giant, customers can support the fight against,breast cancer and help ...
... Inverness Medical,Innovations (Amex: IMA ) today announced ... both core laboratory and point of care,diagnostic testing products ... Inverness will pay an earn out up to a ... had,revenues of approximately $29.5m in 2006 and has been ...
... Workers in PA, MI, IL, FL, OH, MD, WI, WA Join Forces in, ... Equity ... Buyout, WASHINGTON, Oct. 3 ... union today,is launching a multi-state grassroots campaign calling on global buyout,giant the Carlyle ...
Cached Medicine News:Health News:Ralphs 'Pink Tag' Campaign to Raise $170,000 for Breast Cancer Awareness in October 2Health News:Safe to Stop the Flow?: Differing Attitudes Found Between Women and Doctors Concerning Menstrual Suppression 2Health News:Safe to Stop the Flow?: Differing Attitudes Found Between Women and Doctors Concerning Menstrual Suppression 3Health News:Differing attitudes found between women and doctors concerning menstrual suppression 2Health News:Stop & Shop and Giant Food Join General Mills in Pink for the Cure 2Health News:Inverness Medical Innovations Acquires Bio-Stat Healthcare Group 2Health News:SEIU Launches Multi-State Grassroots Campaign Calling on the Carlyle Group to Put Care Above Profits in Buyout of Nation's Largest Nursing Home Chain 2
(Date:7/29/2015)... Calif. , July 29, 2015 Daiichi ... Daiichi Sankyo Group, announced today that The New ... results demonstrating that the investigational drug, PLX3397, an oral ... patients with tenosynovial giant cell tumor (TGCT), a rare, ... Following phase 1 dose-escalation, which evaluated the ...
(Date:7/29/2015)... MONROVIA, Calif., July 29, 2015  STAAR Surgical Company (NASDAQ: ... implantable lenses and delivery systems for the eye today reported ... Second Quarter Overview , Net Sales ... , Unfavorable Currency Impact of $2.1 Million from the ... in EMEA and 13% in China , APAC Sales ...
(Date:7/29/2015)... Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ), today announced ... June 30, 2015. "We are impressed with ... Mihael H. Polymeropoulos M.D., Vanda,s President and CEO, "further ... our products set the stage for the next level ... , Total net product sales for the second ...
Breaking Medicine Technology:Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients 2Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients 3Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients 4Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients 5STAAR Surgical Reports Second Quarter 2015 Results 2STAAR Surgical Reports Second Quarter 2015 Results 3STAAR Surgical Reports Second Quarter 2015 Results 4STAAR Surgical Reports Second Quarter 2015 Results 5STAAR Surgical Reports Second Quarter 2015 Results 6STAAR Surgical Reports Second Quarter 2015 Results 7STAAR Surgical Reports Second Quarter 2015 Results 8STAAR Surgical Reports Second Quarter 2015 Results 9STAAR Surgical Reports Second Quarter 2015 Results 10STAAR Surgical Reports Second Quarter 2015 Results 11STAAR Surgical Reports Second Quarter 2015 Results 12STAAR Surgical Reports Second Quarter 2015 Results 13STAAR Surgical Reports Second Quarter 2015 Results 14STAAR Surgical Reports Second Quarter 2015 Results 15STAAR Surgical Reports Second Quarter 2015 Results 16STAAR Surgical Reports Second Quarter 2015 Results 17STAAR Surgical Reports Second Quarter 2015 Results 18STAAR Surgical Reports Second Quarter 2015 Results 19STAAR Surgical Reports Second Quarter 2015 Results 20STAAR Surgical Reports Second Quarter 2015 Results 21STAAR Surgical Reports Second Quarter 2015 Results 22STAAR Surgical Reports Second Quarter 2015 Results 23STAAR Surgical Reports Second Quarter 2015 Results 24Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 2Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 3Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 4Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 5Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 6Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 7Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 8Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 9
... May 7 Shire plc (LSE: SHP,Nasdaq: ... findings from a new data analysis that ... (methylphenidate transdermal,system) between boys and girls aged ... Disorder (ADHD). The findings from the analysis ...
... III Data Presented at American Psychiatric Association Annual ... Inc.,(NYSE: FRX ) announced today that study ... depression as compared to,placebo treatment and was well ... (MDD), according to phase III data presented at,the ...
Cached Medicine Technology:New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 2New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 3New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 4New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 5New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 6New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 7Study Demonstrates Lexapro(R) Significantly Improves Depression Symptoms in Adolescents 2Study Demonstrates Lexapro(R) Significantly Improves Depression Symptoms in Adolescents 3Study Demonstrates Lexapro(R) Significantly Improves Depression Symptoms in Adolescents 4Study Demonstrates Lexapro(R) Significantly Improves Depression Symptoms in Adolescents 5Study Demonstrates Lexapro(R) Significantly Improves Depression Symptoms in Adolescents 6
... Systems Orthokeratology (oprifocon A) Contact Lenses ... used for orthokeratology, a process that ... wears these lenses overnight and removes ... day, nearsightedness is temporarily corrected or ...
... a way to help your patients with ... Based on the outcomes of several ... has improved the quality of their lives; ... activities of daily living. , ,MedCath Diagnostics, ...
... 300 ,Oblique 45, ,Type 330 ,Straight, ... by setting the illumination between lenses ... ideal for use in ophthalmology and ... conventional compact microscope can; an advanced ...
... VersaPulse PowerSuite holmium laser combines excellent ... precise, virtually bloodless procedures. It is ... and gall bladder stones of all ... surgical tool. Because its laser light ...
Medicine Products: